Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

HEALTH

The Claim

The majority of Escherichia coli (E. coli) clinical isolates carry Extended-Spectrum Beta-Lactamase (ESBL) enzymes.

Verified by Lenz ·

The Short Version

Available global surveillance and meta-analytic data show fewer than half of all clinical E. coli isolates produce ESBL enzymes. Rates can exceed 50 % in certain hospitals or high-burden regions, but large multicountry datasets from WHO, ECDC, CDC, and a 78-study meta-analysis place the overall prevalence around 42 % or markedly lower in Europe and North America. Therefore, claiming most clinical E. coli isolates carry ESBL enzymes is not supported.

Caveats

  • ESBL prevalence varies sharply by region and care setting; single-center studies cannot stand in for global rates.
  • Key surveillance authorities (WHO, ECDC, CDC) report ESBL rates far below a majority, contradicting the claim.
  • Mixing bloodstream, ICU-specific, and general clinical samples without adjustment distorts the overall picture.

The Receipts

  1. Antimicrobial resistance

    World Health Organization

  2. Antimicrobial resistance surveillance in Europe 2023 – 2021 data

    European Centre for Disease Prevention and Control

  3. GLOBAL PREVALENCE AND ANTIBIOTIC RESISTANCE PATTERNS OF ESBL-PRODUCING ESCHERICHIA COLI IN CLINICAL ISOLATES

    International Journal of Medicine and Public Health [IJMEDPH]

  4. Global prevalence of human intestinal carriage of ESBL-producing E ...

    PubMed

  5. Prevalence and molecular characterization of ESBL-producing ...

    PubMed Central

  6. Seven-Year Surveillance and AI-Based Forecasting of Antimicrobial Resistance in Pediatric Escherichia coli Infections in Northern China (2018–2024) - PMC

    PMC

  7. CDC study highlights growing threat of invasive E coli - CIDRAP

    CIDRAP

  8. Comparison of Epidemiological Characteristics Between ESBL and Non-ESBL Isolates of Clinically Isolated Escherichia coli from 2014 to 2022: A Single-Center Study - PMC

    PMC

  9. Worldwide prevalence of extended-spectrum β-lactamases-producing uropathogenic Escherichia coli isolates among kidney transplant patients: a systematic review and meta-analysis - PMC

    PMC

  10. Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019 - PubMed

    PubMed

+ 11 more sources — see the full list on Lenz

Filed Under

Escherichia coliExtended-Spectrum Beta-Lactamase

More Fact Checks